MEDIAPharma Srl’s mission is to develop new anti-tumor medecines based on modified antibodies capable of recognizing and attacking cancer cells.
The company is participated by a pool of reknown international researchers lead by Professor Stefano Iacobelli from the University of Chieti and Pescara (Italy) as well as the University itself. The remaining associates are INVENT Sarl, a french seed capital company and a well known italian pharmaceutical industry, ABIOGEN Pharma SpA from Pisa.
